35
Participants
Start Date
December 31, 2009
Primary Completion Date
February 28, 2013
Study Completion Date
February 28, 2013
BI-505
Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
Rigshospitalet, Copenhagen
AZ Sint-Jan, Bruges
Ghent University Hospital, Ghent
University of Maryland, Greenebaum Cancer Center, Baltimore
University of Utah Health Sciences Center, Department of Medicine, Division of Hematology, Utah Blood and Marrow Transplant and Myeloma Program, Salt Lake City
Karolinska University Hospital, Huddinge
Hematology Clinic Cancer Division, Skåne University Hospital, Lund
Lead Sponsor
BioInvent International AB
INDUSTRY